Pangaea Oncology S.A. Market Cap ($51.36 Million)
Market Cap & Net Worth: Pangaea Oncology S.A. (PANG)
Pangaea Oncology S.A. market cap. Pangaea Oncology S.A. (MC:PANG) has a market capitalization of $51.36 Million (€43.93 Million) as of November 1, 2026. Listed on the MC stock exchange, this Spain-based company holds position #21620 globally and #157 in its home market, demonstrating a 2.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pangaea Oncology S.A.'s stock price €1.47 by its total outstanding shares 35913427 (35.91 Million). Also see Pangaea Oncology S.A. cash conversion from operations for how efficiently the company converts equity into cash flow.
Pangaea Oncology S.A. Market Cap History (2016–2026)
Pangaea Oncology S.A. market cap history from 2016 to 2026. Data shows change from $112.01 Million to $61.72 Million (-5.32% CAGR). Check Pangaea Oncology S.A. stock price for real-time trading data and today's change.
Pangaea Oncology S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pangaea Oncology S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Pangaea Oncology S.A. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.00x
Pangaea Oncology S.A.'s market cap is 5.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $112.01 Million | $2.52 Million | -$594.53K | 44.48x | N/A |
| 2017 | $87.37 Million | $2.62 Million | -$1.65 Million | 33.33x | N/A |
| 2018 | $84.05 Million | $3.06 Million | -$1.25 Million | 27.48x | N/A |
| 2019 | $70.34 Million | $3.32 Million | -$4.84 Million | 21.21x | N/A |
| 2020 | $66.20 Million | $4.10 Million | -$1.79 Million | 16.15x | N/A |
| 2021 | $64.96 Million | $4.60 Million | -$641.91K | 14.11x | N/A |
| 2022 | $68.86 Million | $4.37 Million | -$2.71 Million | 15.77x | N/A |
| 2023 | $77.26 Million | $8.00 Million | -$4.66 Million | 9.66x | N/A |
| 2024 | $74.32 Million | $14.27 Million | -$1.17 Million | 5.21x | N/A |
| 2025 | $72.64 Million | $14.52 Million | -$3.60 Million | 5.00x | N/A |
Competitor Companies of PANG by Market Capitalization
Companies near Pangaea Oncology S.A. in the global market cap rankings as of November 1, 2026. Also see Pangaea Oncology S.A. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Pangaea Oncology S.A. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Pangaea Oncology S.A. (2016–2026)
Market capitalization of Pangaea Oncology S.A. from 2016 to today. Between 2016 and today, Pangaea Oncology S.A.'s market cap moved from $112.01 Million to $ 61.72 Million, with a yearly change of -5.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €61.72 Million | -15.03% |
| 2025 | €72.64 Million | -2.26% |
| 2024 | €74.32 Million | -3.80% |
| 2023 | €77.26 Million | +12.20% |
| 2022 | €68.86 Million | +6.00% |
| 2021 | €64.96 Million | -1.88% |
| 2020 | €66.20 Million | -5.88% |
| 2019 | €70.34 Million | -16.31% |
| 2018 | €84.05 Million | -3.80% |
| 2017 | €87.37 Million | -22.00% |
| 2016 | €112.01 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Pangaea Oncology S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.36 Million USD |
| MoneyControl | $51.36 Million USD |
| MarketWatch | $51.36 Million USD |
| marketcap.company | $51.36 Million USD |
| Reuters | $51.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more